THE EUROPEAN MEDICINES AGENCY'S STRATEGIES TO TACKLE THE CHALLENGES OF AD DRUG DEVELOPMENT

被引：0
|
作者：
Mantua, Valentina [1 ]
机构：
[1] AIFA, Rome, Italy
来源：
NEUROBIOLOGY OF AGING | 2016年 / 39卷
关键词：
Alzheimer's disease; Regulatory;
D O I：
10.1016/j.neurobiolaging.2016.01.038
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [21] European Medicines Agency guidelines to increase the pace of biosimilar development
    Parks, Lisa
    BIOANALYSIS, 2012, 4 (22) : 2665 - 2665
  • [22] Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
    Manolis, Efthymios
    Garcia-Arieta, Alfredo
    Lindahl, Anders
    Kotzagiorgis, Evangelos
    Limberg, Jobst
    Holte, Oyvind
    Paixao, Paulo
    Versantvoort, Carolien
    Tshinanu, Flora Musuamba
    Blake, Kevin
    Van den Heuvel, Michiel
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (05): : 556 - 559
  • [23] The European Medicines Agency's goals for regulatory science to 2025
    Hines, Philip A.
    Guy, Richard H.
    Humphreys, Anthony J.
    Papaluca-Amati, Marisa
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (06) : 403 - 404
  • [24] A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database
    Stefania Chiappini
    Fabrizio Schifano
    CNS Drugs, 2016, 30 : 647 - 654
  • [25] A future for regulatory science in the European Union: the European Medicines Agency’s strategy
    Philip A. Hines
    Rosanne Janssens
    Rosa Gonzalez-Quevedo
    Apolline I.O.M. Lambert
    Anthony J. Humphreys
    Nature Reviews Drug Discovery, 2020, 19 : 293 - 294
  • [26] A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database
    Chiappini, Stefania
    Schifano, Fabrizio
    CNS DRUGS, 2016, 30 (07) : 647 - 654
  • [27] A future for regulatory science in the European Union: the European Medicines Agency's strategy
    Hines, Philip A.
    Janssens, Rosanne
    Gonzalez-Quevedo, Rosa
    Lambert, Apolline I. O. M.
    Humphreys, Anthony J.
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (05) : 293 - 294
  • [28] Impact of the Food and Drug Administration (FDA)-European Medicines Agency (EMA) Common Commentary (CC) on Paediatric Cancer Drug Development
    Reaman, G.
    Herold, R.
    Norga, K.
    Donoghue, M.
    Casey, D.
    Chuk, M.
    Dinndorf, P.
    Leighton, J.
    Sterba, J.
    Paulo, P.
    Baiardi, P.
    van den Berg, H.
    Carleer, J.
    Suzanne, M.
    Temeck, J.
    Murphy, D.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S212 - S212
  • [29] More Efficient Compliance with European Medicines Agency and Food and Drug Administration Regulations for Pediatric Oncology Drug Development: Problems and Solutions
    Milne, Christopher-Paul
    CLINICAL THERAPEUTICS, 2017, 39 (02) : 238 - 245
  • [30] The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
    Butlen-Ducuing, Florence
    Haberkamp, Marion
    Aislaitner, Georgios
    Balkowiec-Iskra, Ewa
    Mattila, Taina
    Doucet, Marika
    Kollb-Sielecka, Marta
    Balabanov, Pavel
    Leuchs, Ann-Kristin
    Elferink, Andre
    EUROPEAN PSYCHIATRY, 2023, 67 (01)
12345